Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer
Background. Colorectal cancers (CRC) shed DNA into blood circulation. There is growing evidence that the analysis of circulating tumor DNA can be effectively used for monitoring of disease, to track tumor heterogeneity and to evaluate response to treatment. Case Presentation. Here, we describe two c...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/6139634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173864548499456 |
|---|---|
| author | Jörg Trojan Susanne Klein-Scory Christine Koch Wolff Schmiegel Alexander Baraniskin |
| author_facet | Jörg Trojan Susanne Klein-Scory Christine Koch Wolff Schmiegel Alexander Baraniskin |
| author_sort | Jörg Trojan |
| collection | DOAJ |
| description | Background. Colorectal cancers (CRC) shed DNA into blood circulation. There is growing evidence that the analysis of circulating tumor DNA can be effectively used for monitoring of disease, to track tumor heterogeneity and to evaluate response to treatment. Case Presentation. Here, we describe two cases of patients with advanced CRC. The first case is about a patient with no available tissue for analysis of RAS mutation status. Liquid biopsy revealed RAS-wild-type and the therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibody cetuximab could be initiated. In the second case, the mutational profile of a patient with initial wild-type RAS-status was continually tracked during the course of treatment. An acquired KRAS exon 3 mutation was detected. The number of KRAS mutated fragments decreased continuously after the discontinuation of the therapy with EGFR-specific antibodies. Conclusion. Liquid biopsy provides a rapid genotype result, which accurately reproduces the current mutation status of tumor tissue. Furthermore, liquid biopsy enables close monitoring of the onset of secondary resistance to anti-EGFR therapy. |
| format | Article |
| id | doaj-art-d4122c81b00a47e9b2307c05585945d5 |
| institution | OA Journals |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-d4122c81b00a47e9b2307c05585945d52025-08-20T02:19:45ZengWileyCase Reports in Oncological Medicine2090-67062090-67142017-01-01201710.1155/2017/61396346139634Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal CancerJörg Trojan0Susanne Klein-Scory1Christine Koch2Wolff Schmiegel3Alexander Baraniskin4Gastroenterology, Department of Medicine, Goethe University Frankfurt, Frankfurt, GermanyIMBL Medical Clinic, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, GermanyGastroenterology, Department of Medicine, Goethe University Frankfurt, Frankfurt, GermanyIMBL Medical Clinic, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, GermanyIMBL Medical Clinic, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, GermanyBackground. Colorectal cancers (CRC) shed DNA into blood circulation. There is growing evidence that the analysis of circulating tumor DNA can be effectively used for monitoring of disease, to track tumor heterogeneity and to evaluate response to treatment. Case Presentation. Here, we describe two cases of patients with advanced CRC. The first case is about a patient with no available tissue for analysis of RAS mutation status. Liquid biopsy revealed RAS-wild-type and the therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibody cetuximab could be initiated. In the second case, the mutational profile of a patient with initial wild-type RAS-status was continually tracked during the course of treatment. An acquired KRAS exon 3 mutation was detected. The number of KRAS mutated fragments decreased continuously after the discontinuation of the therapy with EGFR-specific antibodies. Conclusion. Liquid biopsy provides a rapid genotype result, which accurately reproduces the current mutation status of tumor tissue. Furthermore, liquid biopsy enables close monitoring of the onset of secondary resistance to anti-EGFR therapy.http://dx.doi.org/10.1155/2017/6139634 |
| spellingShingle | Jörg Trojan Susanne Klein-Scory Christine Koch Wolff Schmiegel Alexander Baraniskin Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer Case Reports in Oncological Medicine |
| title | Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer |
| title_full | Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer |
| title_fullStr | Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer |
| title_full_unstemmed | Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer |
| title_short | Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer |
| title_sort | clinical application of liquid biopsy in targeted therapy of metastatic colorectal cancer |
| url | http://dx.doi.org/10.1155/2017/6139634 |
| work_keys_str_mv | AT jorgtrojan clinicalapplicationofliquidbiopsyintargetedtherapyofmetastaticcolorectalcancer AT susannekleinscory clinicalapplicationofliquidbiopsyintargetedtherapyofmetastaticcolorectalcancer AT christinekoch clinicalapplicationofliquidbiopsyintargetedtherapyofmetastaticcolorectalcancer AT wolffschmiegel clinicalapplicationofliquidbiopsyintargetedtherapyofmetastaticcolorectalcancer AT alexanderbaraniskin clinicalapplicationofliquidbiopsyintargetedtherapyofmetastaticcolorectalcancer |